Related Experiment Video
Updated: Sep 16, 2025

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Exogenous activation of the adhesion GPCR ADGRD1/GPR133 protects against bone loss by negatively regulating
Liang He1, Qiansen Zhang2, Yu You1
1Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai, PR. China.
Abstract:
Adhesion G protein-coupled receptors (GPCRs) play crucial roles in numerous physiological and pathological conditions. However, the functions of adhesion GPCRs remain poorly understood because of the lack of effective modulators. Here, we used the adhesion GPCR D1 (ADGRD1/GPR133) as a model to unveil a strategy for finding exogenous agonists that target adhesion GPCRs while revealing previously unidentified functions of ADGRD1. We identified the small molecule GL64 as a selective agonist of ADGRD1. GL64 activates ADGRD1 by mimicking the stachel sequence. Using GL64 as a chemical tool, we demonstrated that ADGRD1 negatively regulates bone loss by inhibiting osteoclastogenesis. The cAMP-PKA-NFATC1 pathway was identified as the downstream signaling pathway of ADGRD1 in osteoclasts. Furthermore, administering GL64 prevented bone loss and suppressed osteoclast activity in the osteoporosis mouse model induced by ovariectomy. Our findings provide mechanistic insights into the activation of adhesion GPCRs by exogenous agonists and underscore the therapeutic potential of targeting ADGRD1 in osteoclast-related diseases.
Insights
Researchers identified GL64, a novel agonist for adhesion G protein-coupled receptor D1 (ADGRD1). This discovery reveals ADGRD1
Area of Science:
- Biochemistry
- Pharmacology
- Cell Biology
Background:
- Adhesion G protein-coupled receptors (GPCRs) are vital in health and disease.
- Understanding adhesion GPCR functions is limited by a lack of specific modulators.
Purpose of the Study:
- To develop a strategy for identifying exogenous agonists targeting adhesion GPCRs.
- To explore the functions of adhesion GPCR D1 (ADGRD1/GPR133).
Main Methods:
- Small molecule screening to identify ADGRD1 agonists.
- Utilizing the identified agonist (GL64) as a chemical probe.
- Investigating ADGRD1's role in osteoclastogenesis and bone loss using cellular and mouse models.
Main Results:
- GL64 was identified as a selective agonist for ADGRD1, mimicking the stachel sequence.
- ADGRD1 was found to negatively regulate bone loss by inhibiting osteoclastogenesis via the cAMP-PKA-NFATC1 pathway.
- GL64 administration in an osteoporosis mouse model prevented bone loss and reduced osteoclast activity.
Conclusions:
- A novel strategy for activating adhesion GPCRs with exogenous agonists was established.
- ADGRD1 plays a significant role in regulating bone metabolism.
- Targeting ADGRD1 presents therapeutic potential for osteoclast-related diseases like osteoporosis.
Related Concept Videos
Osteoclasts in Bone Remodeling
GPCRs Regulate Adenylyl Cylase Activity
Bone Remodeling
GPCR Desensitization
TGF - β Signaling Pathway
Activation and Inactivation of G Proteins

